Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 16/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844883 | 1.00 | CACNA1B (0.46) | CACNA1BNR1I2CYP3A4CCR5LMNA | |
| SCHEMBL2851102 | 0.93 | CACNA1B (0.44) | CACNA1BNR1I2CYP3A4LMNAGAA | |
| SCHEMBL2851104 | 0.93 | CACNA1B (0.44) | CACNA1BNR1I2CYP3A4LMNAGAA | |
| SCHEMBL2844916 | 0.83 | CACNA1B (0.49) | CACNA1BNR1I2LMNA | |
| SCHEMBL2844918 | 0.83 | CACNA1B (0.49) | CACNA1BNR1I2LMNA | |
| SCHEMBL2846617 | 0.83 | CACNA1B (0.49) | CACNA1BNR1I2LMNA | |
| SCHEMBL65958 | 0.82 | CACNA1B (0.51) | CACNA1BNR1I2GAA | |
| SCHEMBL65957 | 0.82 | CACNA1B (0.51) | CACNA1BNR1I2GAA | |
| SCHEMBL16497847 | 0.81 | CACNA1B (0.46) | CACNA1BCCR5 | |
| SCHEMBL67771 | 0.81 | CACNA1B (0.46) | CACNA1BCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | claimed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CACNA1B 5/4885NR1I2 1953/4885CYP3A4 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.